Tokyo, Nov. 24 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059859) titled 'Radio-Frequency-Ablation for lung cancer under general anesthesia' on Nov. 24.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Kashiwa Kousei General Hospital

Condition: Condition - Malignant pulmonary tumors Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To increase accuracy of hitting radiofrequency ablation needle and decrease pain during the treatment. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Before radiofrequency for malignant pulmonary tumors, general anesthesia with tracheal intubation is conducted at CT room, following by radiofrequency ablation.

Eligibility: Age-lower limit - 15 years-old = Gender - Male and Female Key inclusion criteria - 1.Primary lung tumors or metastatic lung tumors. 2.The tumor is smaller than 5cm, and the number of tumors is less than 5. 3. Standard therapy, such as surgery, chemotherapy, and radiation therapy, is hard to control the tumor. 4. Patients request the radiofrequency ablation rather than the standard therapy, such as surgery, chemotherapy, and radiation therapy. 5. Patients with multiple metastatic tumors, who are expected to survival long after radiofrequency ablation for large lung tumors. 6. Performance status is lower than 2. Key exclusion criteria - 1. Severe clinical symptoms. 2. Unsuitable status judged by doctor in charge. Target Size - 100

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2023 Year 03 Month 20 Day Date of IRB - 2023 Year 03 Month 20 Day Anticipated trial start date - 2023 Year 03 Month 20 Day Last follow-up date - 2035 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057458

Disclaimer: Curated by HT Syndication.